Written answers

Thursday, 20 February 2025

Department of Health

Vaccination Programme

Photo of Emer CurrieEmer Currie (Dublin West, Fine Gael)
Link to this: Individually | In context | Oireachtas source

345. To ask the Minister for Health if she will consider rolling out the shingles vaccine through the National Immunisation Programme to people aged 70 years and over and to those who are immunocompromised over 50 years as has been done in other states in the EU, the UK, Australia and New Zealand; if other supports are available to cut the cost of vaccination (details supplied). [6923/25]

Photo of Kieran O'DonnellKieran O'Donnell (Limerick City, Fine Gael)
Link to this: Individually | In context | Oireachtas source

Shingles vaccination is not currently provided as part of the national immunisation programme but it is open to any individual who is aged 50 years and older and who wishes to receive the vaccine to consult with their GP or pharmacist.

The ages at which vaccines are recommended in the national immunisation programme are chosen by the National Immunisation Advisory Committee (NIAC) in order to give each individual the best possible protection against vaccine preventable diseases.

The Health Information and Quality Authority (HIQA) recently carried out a Health Technology Assessment (HTA) on the herpes zoster vaccine which protects against shingles. A HTA is a multidisciplinary research process that collects and summarises information about a health technology. The information can cover a range of fields, including clinical effectiveness and safety, cost-effectiveness and budget impact, organisational and social aspects, and ethical and legal issues. The information is collected and presented in a systematic, unbiased and transparent manner.

HIQA published the HTA on 19 July 2024. The HTA found that adding the shingles vaccine to the schedule is not cost effective and is associated with a substantial budget impact. My Department has considered its findings and determined that the introduction of the vaccine can be reconsidered when cost effectiveness is more favourable.

Comments

No comments

Log in or join to post a public comment.